SETD1A and prostate carcinoma: A study conducted by our group has recently revealed that SETD1A, which is present at higher levels in metastatic castrate-resistant prostate cancer (mCRPC) than in primary prostate cancer cells, contributes to the tri-methylation of H3K4 by binding to E2F1 in the promoter region of the FOXM1 gene, a cancer cell proliferation-specific transcription factor.